Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 3/20 | 0.34 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29887844 | 0.85 | KMT2A (0.44) | FGFR1ERBB2MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL24569478 | 0.85 | KMT2A (0.44) | FGFR1ERBB2MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL31475721 | 0.84 | FGFR1 (0.41) | FGFR1ERBB2MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL31476077 | 0.83 | GRM5 (0.30) | — | |
| SCHEMBL31476211 | 0.80 | HPGD (0.31) | HCAR3HPGD | |
| SCHEMBL31257583 | 0.75 | HCAR3 (0.37) | MAPTALDH1A1SMN1; SMN2HCAR3HPGD | |
| SCHEMBL31257494 | 0.74 | NPC1 (0.47) | MAPTALDH1A1SMN1; SMN2HPGDLMNA | |
| SCHEMBL30050420 | 0.73 | GRM5 (0.42) | ERBB2 | |
| SCHEMBL24807701 | 0.73 | GRM5 (0.42) | ERBB2 | |
| SCHEMBL31475856 | 0.73 | HCAR3 (0.30) | MAPTHCAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129078-A1 | ERBB2 INHIBITORS | COGENT BIOSCIENCES, INC. | 2025-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129078-A1 | ERBB2 INHIBITORS | ERBB2, ERBB3, EGFR | FGFR1 18/4885ERBB2 1/4885MAPT 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.